Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Role of Quality of Life in Hypertension Therapy: Implication for Patient Compliance

      Cardiology

      S. Karger AG

      Hypertension, Quality of life, Patient compliance

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Although the cardiovascular risk factors associated with hypertension are well established, the effects of the disease are usually transparent to the patient. However, the impact of diagnosis and treatment are often overt and usually negative. Because of high rates of non-compliance following adverse experiences with treatment, patients are exposed to the kind of risk for which therapeutic intervention was originally intended. The nature of the impact of hypertension therapy has become more clearly defined as well-controlled, quality-of-life studies have been reported across a variety of therapeutic classes. These studies may be used to address the problem of patient compliance by (1) informing the physician about the likely effects a class of, or particular, compound might have, and (2) by providing a means by which the physician can monitor and intervene in the treatment process. By using quality-of-life information, the clinician can directly influence the impact of therapy on the patient, improve compliance with the therapeutic regimen, and reduce that patient’s risk for cardiovascular events.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-5613-2
          978-3-318-01670-3
          0008-6312
          1421-9751
          1992
          1992
          12 November 2008
          : 80
          : Suppl 1
          : 11-22
          Affiliations
          Pfizer Central Research, Groton, Conn., USA
          Article
          175043 Cardiology 1992;80:11–22
          10.1159/000175043
          1600535
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 12
          Categories
          Session I

          Comments

          Comment on this article